|Bid||79.45 x 800|
|Ask||79.44 x 800|
|Day's Range||78.34 - 79.52|
|52 Week Range||74.13 - 147.17|
|PE Ratio (TTM)||21.83|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.
Celgene is opening its wallet yet again, but to what end? The struggling biotech giant announced Thursday that it plans to spend $2 billion on an accelerated stock repurchase. Celgene’s shares rose early Thursday as they typically do after such announcements, but the pace of Celgene’s buybacks shouldn’t do much to reassure investors.
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
Moody's Investors Service commented that the $2 billion accelerated share repurchase program announced by Celgene Corporation ("Celgene") is credit negative. There is no impact on the company's ratings including the Baa2 senior unsecured long-term rating and the Prime-2 commercial paper rating or stable rating outlook. For additional information please refere to Moody's issuer comment on Celgene available on www.moodys.com.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.
Celgene and General Electric were leaders in Thursday's mixed open, as investors sorted news of new tariffs, and a third straight drop in oil prices.
rose in premarket trading on Thursday, May 24, after the biotech firm said its board had authorized an additional $3 billion of stock buybacks. The Summit, N.J.-based company also said it plans to enter into an accelerated share repurchase agreement (ASR) to buy back $2 billion of stock. "The increase in our share repurchase authorization and planned accelerated share repurchase program reflects our confidence in the long-term potential of Celgene," said Celgene chairman and CEO Mark J. Alles in a statement.
Celgene Corp. shares jumped 1.2% in premarket trade Thursday, after the company announced an additional $3 billion share buyback authorization. The biotech company said it will execute a $2 billion accelerated ...
Wall Street was split Wednesday on Celgene as one sell-side analyst downgraded the stock saying it "has tilted to greater risk" while another upgraded shares.
It's been two years since David's picked a batch of stocks made to thrive in a global society that's ever more focused on the life of the mind.
Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102. By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.
Celgene Corp. sell-side analysts can’t agree on what’s next for the company with shares hovering near a four-year low. Argus analyst David Toung moved to the sidelines on a risk-reward that has “tilted to greater risk” given an over-reliance on one of the world’s biggest brand-name cancer treatments, Revlimid. Shares tumbled on Monday to a four-year low after a news article about the departure of its former business development head, George Golumbeski, added gasoline to the fire of concerns for the drugmaker.
The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.
Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.
After years of growth, Celgene Corporation (NASDAQ:CELG) has spent the past eight months suffering from ever-weakening price action. In fact and with shares of Celgene now off a full 50% from 2017’s all-time-highs following Monday’s 4.70% price drop, you could say bears have been acting with barely any hesitation in CELG stock. The latest ‘disappointment’ in shares of Celgene, judging by Monday’s price reaction, is a report that Celgene’s top dog of business development discreetly retired over a month ago.
Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...
First we gauge the performance of David’s recommendations. Then, he interviews Middleby Corp.'s remarkable leader, Selim Bassoul.
SCYNEXIS (SCYX) witnessed a 28% rise in its stock price in the week ended May 18. On May 18, SCYNEXIS stock closed at $1.63, which is ~14.4% growth from its previous close of $1.43 on May 17. SCYNEXIS stock rose ~27% over the last month. SCYNEXIS is a biotechnology company focused on the development of innovative therapies for the treatment of patients with difficult-to-treat and life-threatening infections.
The S&P 500’s top losses on May 21 were: Fifth Third Bancorp (FITB) declined 7.9%. Celgene (CELG) declined 4.7%. Symantec (SYMC) declined 2.7%. Allergan (AGN) declined 2.7%. Campbell Soup (CPB) declined 2.3%. Fifth Third Bancorp
U.S. biotechnology company Celgene Corp. ( CELG) has entered into a long-term strategic drug discovery and development partnership with Hamburg, Germany-based Evotec AG. In a brief statement, Evotec said it will receive an upfront payment of $65 million for its role in the partnership, as well as the potential to earn “significant milestone payments” and “tiered royalties” on each licensed program. Celgene and Evotec have already partnered up before.
Celgene plunged to another four-year low Monday on a report that an executive in charge of business development quietly retired in mid-April.